Table 4.
Ref. | Design | Cases | Technical success | Clinical success | Complications1 |
Bories et al[86] | RS | 11 | 91% | 80% | 72% |
Maranki et al[87] | RS | 49 | 84% | 80% | 18% |
Brauer et al[88] | PS | 12 | 92% | 72% | 16% |
Horaguchi et al[89] | PS | 16 | 100% | 94% | 37% |
Kim et al[90] | RS | 15 | 80% | 80% | None |
Fabbri et al[91] | PS | 16 | 75% | 75% | 8% |
Park et al[92] | RS | 57 | 96% | 89% | 47% |
Hara et al[93] | PS | 18 | 94% | 94% | 77% |
Komaki et al[94] | RS | 15 | 100% | 100% | 46% |
Ramírez-Luna et al[95] | PS | 11 | 91% | 82% | 18% |
Shah et al[96] | RS | 68 | 85% | 85% | 9% |
Iwashita et al[97] | RS | 40 | 73% | 73% | 12%2 |
Dhir et al[98] | RS | 58 | 98% | 98% | 3% |
Artifon et al[99] | RCT | 13 | 100% | 100% | 15% |
Song et al[100] | PS | 15 | 87% | 87% | 47% |
Kim et al[101] | PS | 13 | 92% | 84% | 38% |
Vila et al[102] | RS | 106 | 70% | 70% | 23% |
Horaguchi et al[103] | RS | 21 | 100% | 100% | 10% |
Hara et al[104] | PS | 18 | 94% | 89% | 27% |
Park et al[105] | PS | 45 | 91% | 87% | 11% |
Kawakubo et al[106] | RS | 14 | 100% | 100% | 14% |
Dhir et al[107] | RS | 35 | 97% | 97% | 23% |
Khashab et al[108] | RS | 35 | 94% | 91% | 14% |
Gornals et al[109] | RS | 15 | 87% | 73% | 40% |
Gupta et al[110] | RS | 240 | 99% | 87% | 35% |
Dhir et al[111] | RS | 68 | 97% | 97% | 21%3 |
Kawakubo et al[112] | RS | 64 | 95% | 95% | 42% |
Total | 27 studies | 1088 | 91% (70%-100%) | 87% (70%-100%) | 29% (3%-77%) |
Complications include: early and late, procedural- and stent-related;
2.5% mortality (1 patient );
4% mortality (3 patients). RCT: Randomized controlled trial; PS: Prospective study; RS: Retrospective study; NR: Not reported.